- centos7搭建shadowsock
- Investors
- English
- linux安装shadowsock
- 日本語
松鼠加速器破解版-outline
For our lead product, Imeglimin, preparations are underway for a New Drug Application in Japan. Imeglimin has successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases.
View Our Candidates
松鼠加速器破解版-outline
Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.
View Pipeline
松鼠加速器破解版-outline
Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team
松鼠加速器破解版-outline
松鼠加速器破解版-outline
Japanese New Drug Application (J-NDA) for Imeglimin is supported by an extensive preclinical and clinical program, including positive results from the Phase 3 TIMES program in over 1,100 patients in Japan Imeglimin…
Read this Press Release: Poxel Announces Submission of Imeglimin Japanese New Drug Application for the Treatment of Type 2 Diabetes by Sumitomo Dainippon Pharma松鼠加速器破解版-outline
Poxel completed a capital raise of EUR 17.7 million (USD 19.4 million) to accelerate development of PXL770 and PXL065 in NASH and to pursue early-stage opportunities for pipeline growth from its…
Read this Press Release: Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2024松鼠加速器破解版-outline
Shareholders approved all proposed resolutions LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for…
Read this Press Release: Poxel Announces Results from June 24, 2024 Ordinary Annual and Extraordinary General Meeting
松鼠加速器破解版-outline
European Association for the Study of the Liver 2024 International Liver Congress
